Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Psychedelic-assisted treatment is at first glance markedly different in structure and approach from mainstream forms of psychotherapy in the West. A major criticism of clinical psychedelic research rests on the difficulty of executing placebo-controlled studies and distinguishing drug effects from those of the psychotherapeutic container in which psychedelics are typically presented. Detractors also tend to find fault in spiritual or mystical themes that often arise in the context of psychedelic use. Common factors theory of psychotherapy is a useful and extensively studied framework that can help make sense of these issues, and has much to contribute to our understanding of contextual effects that are often discussed in psychedelic literature as “set and setting.” In this article, we examine four major contextual “common factors” shared by various healing traditions: 1) the therapeutic relationship; 2) the healing setting; 3) the rationale, conceptual scheme, or myth; and 4) the ritual. We explain how these factors show up in psychedelic-assisted treatment and how they may contribute to therapeutic effects. Lastly, we discuss the implications of these factors for the concept of placebo, and for future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Psychometric properties of the credibility/expectancy questionnaire
Devilly, G. J., & Borkovec, T. D. (2000) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/s0005-7916(00)00012-4 · Cited by 2,295 · cited 1×
“Several questionnaires have been used for expectancy, but the most widely used and applicable measure is the Credibility and Expectancy Questionnaire (CEQ; Devilly & Borkovec, 2000).”
MethodGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 4×
“Email: gukasyan@jhmi.edu In individuals with advanced cancer, psilocybinassisted treatment was associated with marked improvements in symptoms of both anxiety and depression (Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016).”
BackgroundInfluentialThe Great Psychotherapy Debate: The Evidence for What Makes Psychotherapy Work
Wampold, B. E. (2015) · doi:10.4324/9780203582015 · Cited by 1,773
The alliance in adult psychotherapy: A meta-analytic synthesis
Flückiger, C., Del Re, A. C., Wampold, B. E., & Horvath, A. O. (2018) · Psychotherapy · doi:10.1037/pst0000172 · Cited by 1,763 · cited 1×
“A meta-analysis covering studies from 1957–2017, which included more than 30,000 participants, revealed that working alliance was highly correlated with outcomes (r¼ .28, equivalent to a Cohen’s d of .57) (Flückiger et al., 2018).”
MethodHow important are the common factors in psychotherapy? An update
Wampold, B. E. (2015) · World Psychiatry · doi:10.1002/wps.20238 · Cited by 1,728 · cited 1×
“Despite conflicting theories about why any given type of psychotherapy should work, it is rare for one form of psychotherapy to be demonstrated as significantly more effective than another (Wampold, 2015).”
BackgroundRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Research summary on the therapeutic relationship and psychotherapy outcome.
Lambert, M. J., & Barley, D. E. (2001) · Psychotherapy: Theory, Research, Practice, Training · doi:10.1037/0033-3204.38.4.357 · Cited by 1,621 · cited 1×
“Decades of research have reinforced the importance of the therapeutic relationship in psychotherapy, and in many cases it has been demonstrated to be more impactful than a therapist’s adherence to any specialized technique (Lambert & Barley, 2001).”
BackgroundCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 1×
“An open-label study of psilocybin for treatment-resistant depression showed similar decreases in depressive symptoms at 1 week and 3 months (Carhart-Harris et al., 2016).”
BackgroundNichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 2×
“Email: gukasyan@jhmi.edu In individuals with advanced cancer, psilocybinassisted treatment was associated with marked improvements in symptoms of both anxiety and depression (Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016).”
BackgroundHuman hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome
Kaptchuk, T. J., Kelley, J. M., Conboy, L. A., Davis, R. B., Kerr, C. E., Jacobson, E. E., Kirsch, I., Schyner, R. N., Nam, B. H., Nguyen, L. T., et al. (2008) · BMJ · doi:10.1136/bmj.39524.439618.25 · Cited by 1,196
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172 · cited 1×
“For example, we now know that psilocybin exerts its effects via 5-HT2A receptor agonism, and that changes in brain functional connectivity occur during the period of acute drug effects (Carhart-Harris et al., 2012; Quednow et al., 2012).”
BackgroundPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 2×
“…effects from psychotherapy vs. psychedelic is to include a substantial portion of the psychotherapy intervention prior to drug dosing, and to measure changes in primary outcomes between the start of psychotherapy and just prior to the drug session (Anderson et al., 2020; Bogenschutz et al., 2015).”
BackgroundFrank, J. (1993) · doi:10.56021/9780801840678 · Cited by 1,094
Some implicit common factors in diverse methods of psychotherapy.
Rosenzweig, S. (1936) · American Journal of Orthopsychiatry · doi:10.1111/j.1939-0025.1936.tb05248.x · Cited by 1,042 · cited 1×
“An early effort to make sense of this came from Rosenzweig (1936) who posited that factors common to all forms of psychotherapy, rather than specific characteristics of any such treatment, may be responsible for efficacy.”
BackgroundPsilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Long-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Psychedelics and the essential importance of context
Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754710 · Cited by 657
Ahn, H.-N., & Wampold, B. E. (2001) · Journal of Counseling Psychology · doi:10.1037/0022-0167.48.3.251 · Cited by 571
Furukawa, T. A., Noma, H., Caldwell, D. M., Honyashiki, M., Shinohara, K., Imai, H., Chen, P., Hunot, V., & Churchill, R. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12275 · Cited by 521 · cited 2×
“, waitlist-controlled) may contribute to nocebo effects (Furukawa et al., 2014).”
BackgroundElliott, R., Bohart, A. C., Watson, J. C., & Greenberg, L. S. (2011) · Psychotherapy · doi:10.1037/a0022187 · Cited by 511
Hartogsohn, I. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116677852 · Cited by 483 · cited 2×
“Thus far, the literature on this subject has ventured a step further to consider the conceptual similarity between set and setting and placebo effects (Hartogsohn, 2016).”
BackgroundConstructing drug effects: a history of set and setting
Hartogsohn, I. (2017) · Drug Science Policy and Law · doi:10.1177/2050324516683325 · Cited by 472 · cited 1×
“This is often cited as an explanation for varied and contradictory reports of drug effects in early psychedelic research (Hartogsohn, 2017).”
ResultSanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466
Predicting responses to psychedelics: a prospective study
Haijen, E. C. H. M., Kaelen, M., Roseman, L., Timmermann, C., Kettner, H., Russ, S., Nutt, D., Daws, R. E., Hampshire, A. D. G., Lorenz, R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00897 · Cited by 417
Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory
Roseman, L., Haijen, E., Idialu-Ikato, K., Kaelen, M., Watts, R., & Carhart-Harris, R. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119855974 · Cited by 413 · cited 2×
“A variety of psychological explanations have been proposed for the immediate and longer term efficacy of psychedelics, including improvements in psychological insight, emotional breakthrough, cognitive flexibility, ego-dissolution, and mystical or peak experiences (Davis et al., 2020; Garcia-Romeu et al., 2019; Griffi…”
BackgroundDavis, A. K., Barrett, F. S., & Griffiths, R. R. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.004 · Cited by 375 · cited 2×
“A variety of psychological explanations have been proposed for the immediate and longer term efficacy of psychedelics, including improvements in psychological insight, emotional breakthrough, cognitive flexibility, ego-dissolution, and mystical or peak experiences (Davis et al., 2020; Garcia-Romeu et al., 2019; Griffi…”
BackgroundThe efficacy of non-directive supportive therapy for adult depression: A meta-analysis
Cuijpers, P., Driessen, E., Hollon, S. D., van Oppen, P., Barth, J., & Andersson, G. (2012) · Clinical Psychology Review · doi:10.1016/j.cpr.2012.01.003 · Cited by 369
Self unbound: ego dissolution in psychedelic experience
Letheby, C., & Gerrans, P. (2017) · Neuroscience of Consciousness · doi:10.1093/nc/nix016 · Cited by 293 · cited 1×
“…term efficacy of psychedelics, including improvements in psychological insight, emotional breakthrough, cognitive flexibility, ego-dissolution, and mystical or peak experiences (Davis et al., 2020; Garcia-Romeu et al., 2019; Griffiths et al., 2016; Letheby & Gerrans, 2017; Roseman et al., 2019).”
BackgroundAnderson, B. T., Danforth, A., Daroff, P. R., Stauffer, C., Ekman, E., Agin-Liebes, G., Trope, A., Boden, M. T., Dilley, P. J., Mitchell, J., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100538 · Cited by 284
Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature.
Michaels, T. I., Purdon, J., Collins, A., & Williams, M. T. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1824-6 · Cited by 265 · cited 1×
“Researchers have also been criticized for employing non-representative samples composed mostly of highly educated White participants (Michaels et al., 2018).”
BackgroundYounger, J., Gandhi, V., Hubbard, E., & Mackey, S. (2012) · Clinical Trials · doi:10.1177/1740774512465064 · Cited by 212 · cited 1×
“The Stanford Expectations of Treatment Scale (SETS) is another more recently created measure that could also be useful for examining expectancy (Younger et al., 2012).”
BackgroundWeinman, J., Petrie, K. J., Sharpe, N., & Walker, S. (2000) · British Journal of Health Psychology · doi:10.1348/135910700168900 · Cited by 202 · cited 1×
“A patient’s EM can have consequences for adherence to treatment and outcomes (Galli et al., 2010; Halm et al., 2006; Weinman et al., 2000).”
BackgroundAre the parts as good as the whole? A meta-analysis of component treatment studies.
Bell, E. C., Marcus, D. K., & Goodlad, J. K. (2013) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0033004 · Cited by 192 · cited 2×
“In two meta-analyses of “dismantling” studies, in which the effects of removing a single specific ingredient are examined, removal of one or more “critical” elements of treatment resulted in no statistically significant change in treatment efficacy (Ahn & Wampold, 2001; Bell et al., 2013).”
BackgroundResultCarbonaro, T. M., Johnson, M. W., Hurwitz, E., & Griffiths, R. R. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4769-4 · Cited by 133 · cited 3×
“Comparator drug conditions such as very low dose psychedelic compounds, dextromethorphan, and methylphenidate have been used in other studies (Griffiths et al., 2006, 2016; Carbonaro et al., 2018).”
BackgroundNeuroticism is associated with challenging experiences with psilocybin mushrooms
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2017) · Personality and Individual Differences · doi:10.1016/j.paid.2017.06.004 · Cited by 98 · cited 1×
“Barrett et al. (2017) have demonstrated that higher levels of trait neuroticism are associated with higher likelihood of challenging experiences.”
BackgroundControlling for the placebo effect in psychotherapy: Noble quest or tilting at windmills?
Kirsch, I., Wampold, B., & Kelley, J. M. (2016) · Psychology of Consciousness: Theory, Research, and Practice · doi:10.1037/cns0000065 · Cited by 71 · cited 2×
“As summarized by Kirsch et al. (2016): The placebo effect in medicine is produced by factors other than the physical properties of the treatment.”
BackgroundMurrough, J. W., Stade, E., Sayed, S., Ahle, G., Kiraly, D. D., Welch, A., Collins, K. A., Soleimani, L., Iosifescu, D. V., & Charney, D. S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.072 · Cited by 62 · cited 1×
“Dextromethorphan is a dissociative anesthetic and works by a different mechanism than psilocybin, yet has also been hypothesized to have some antidepressant effects (Lauterbach, 2011; Murrough et al., 2017).”
Background
Cited by
Blinding and expectancy confounds in psychedelic randomized controlled trials
Muthukumaraswamy, S. D., Forsyth, A., & Lumley, T. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933434 · Cited by 324
Aday, J. S., Heifets, B. D., Pratscher, S. D., Bradley, E., Rosen, R., & Woolley, J. D. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06123-7 · Cited by 237
Sloshower, J., Skosnik, P. D., Safi-Aghdam, H., Pathania, S., Syed, S., Pittman, B., & D’Souza, D. C. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231154852 · Cited by 165
Expectancy in placebo-controlled trials of psychedelics: if so, so what?
Butler, M., Jelen, L., & Rucker, J. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06221-6 · Cited by 100
“Many modern trials of psychedelics thus share aspects integral to trials of psychological therapies, as opposed to being purely medication trials, and it is difficult (and arguably not useful) to wholly distinguish the effects of medication versus therapy (Gukasyan and Nayak 2021).”
BackgroundBender, D., & Hellerstein, D. J. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06049-6 · Cited by 88
Metadata
- Authors
- Gukasyan, N., & Nayak, S. M.
- Venue
- Transcultural Psychiatry
- Publisher
- SAGE Publications
- Published
- 2021-01-26
- Volume
- 59
- Issue
- 5
- Pages
- 652-664
- ISSN
- 1363-4615 (ISSN-L)
- 1461-7471
- OpenAlex
- W3122951191
- Cited by
- 150
- References
- 43
- FWCI
- 16.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.